Skip to main content
Equibles
IMNN logo

IMNN · Imunon, Inc.

Track IMNN — free

Use IMNN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IMNN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.65 +0.07 (+4.43%) At close · Aug 14
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$9.26M
Shares
5.61M

Imunon, Inc. Earnings Call Transcripts

Every quarterly earnings call for Imunon, Inc. (IMNN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0% $125,000 −$6.15M '22 Q3 22-11-14 LATEST ▲0% $125,000 −$13.23M '22 Q4 23-03-30
Earnings call
FY26 · Q2
2026-08-11
Imunon, Inc. Q2 FY2026 Earnings Call
Confident tone MRD translational/biomarker validation Phase III Ovation III enrollment momentum Safety profile of Immunon-001
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Imunon, Inc. Q1 FY2026 Earnings Call
Positive tone FDA pathway and overall survival endpoint Phase 2 Ovation 2 results Phase 3 Ovation 3 enrollment
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Imunon, Inc. Q4 FY2025 Earnings Call
Confident tone OVATION 2 Phase II overall survival data OVATION 3 Phase III trial enrollment Regulatory and trial design validation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Imunon, Inc. Q3 FY2025 Earnings Call
Confident tone IMNN-001 Clinical Data & Mechanism OVATION 3 Trial Enrollment & Progress Regulatory Pathway & Trial Design
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Imunon, Inc. Q2 FY2025 Earnings Call
Confident tone IMNN-001 OVATION 3 Phase III Trial OVATION 2 Survival Data and ASCO Presentation Regulatory Strategy and Endpoints
Diluted EPS
$-2.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Imunon, Inc. Q1 FY2025 Earnings Call
Confident tone Phase III OVATION 3 trial initiation OVATION 2 results and ASCO presentation IMNN-001 for ovarian cancer
Diluted EPS
$-3.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Imunon, Inc. Q4 FY2024 Earnings Call
Confident tone Imunon-001 OVATION 2 Phase 2 Results Phase 3 OVATION 3 Initiation Translational and Dose-Response Data
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Imunon, Inc. Q3 FY2024 Earnings Call
Confident tone OVATION 2 Phase 2 results Commercial opportunity and market sizing TheraPlas platform and IL-12 mechanism
Diluted EPS
$-3.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Imunon, Inc. Q2 FY2024 Earnings Call
Confident tone IMNN-101 COVID-19 vaccine and PlaCCine platform IMNN-001 / OVATION 2 Phase 2 ovarian cancer results Partnership strategy and non-dilutive funding
Diluted EPS
$-6.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Imunon, Inc. Q1 FY2024 Earnings Call
Positive tone IMNN-001 / OVATION 2 ovarian cancer readout DNA-based technology platforms New CEO transition
Diluted EPS
$-6.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Imunon, Inc. Q4 FY2023 Earnings Call
Confident tone IMNN-101 Seasonal COVID-19 Vaccine and PlaCCine Platform Regulatory and FDA Engagement TheraPlas Platform and IL-12 Immunotherapy
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Imunon, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-4.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Imunon, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-7.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Imunon, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-8.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Imunon, Inc. Q4 FY2022 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Imunon, Inc. Q3 FY2022 Earnings Call
Revenue
$125,000
▲ 0% YoY
Diluted EPS
$-11.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Imunon, Inc. Q2 FY2022 Earnings Call
Revenue
$125,000
▲ 0% YoY
Diluted EPS
$-11.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Imunon, Inc. Q1 FY2022 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Imunon, Inc. Q4 FY2021 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Imunon, Inc. Q3 FY2021 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Imunon, Inc. Q2 FY2021 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Imunon, Inc. Q1 FY2021 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-19
Imunon, Inc. Q4 FY2020 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-16
Imunon, Inc. Q3 FY2020 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-14
Imunon, Inc. Q2 FY2020 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Imunon, Inc. Q1 FY2020 Earnings Call
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Imunon, Inc. Q4 FY2019 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 749647 CUSIP 15117N701 13F (30d) 25 filings 24 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)